Home/Hedge Fund Intelligence/Neurocrine Biosciences Inc
Nasdaq: NBIXStockForm 13F30 Jun 2026

Hedge funds that hold Neurocrine Biosciences Inc Nasdaq: NBIX

CUSIP 64125C109 · who reports it, how much, and how much it matters to them

35 of the 720 hedge fund managers we track reported shares of Neurocrine Biosciences Inc (Nasdaq: NBIX) on Form 13F for 30 June 2026. Between them they reported USD 1.4bn. The largest position belongs to Renaissance Technologies, at USD 394m. The manager with the most riding on it is Sarissa Capital Management, where it is 11.0% of the reported book.

Managers reporting it35of 720 we track
Value they reportUSD 1.4bnshares only, 30 Jun 2026
Funds they run512with a file on PPLI.com
Largest positionUSD 394mRenaissance Technologies
Typical weight0.1%median share of a manager's book
Heaviest weight11.0%Sarissa Capital Management

Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated

Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.

13F
What this page is

A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.

Who holds it

35 managers, USD 1.4bn between them

Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.

Every manager that reports Neurocrine Biosciences Inc, largest position first

The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.

#ManagerValue reportedShare of its book
1Renaissance Technologies13 funds on PPLI.comUSD 394m0.5%
2Two Sigma Investments35 funds on PPLI.comUSD 350m0.3%
3RTW Investments2 funds on PPLI.comUSD 214m1.8%
4Armistice Capital1 fund on PPLI.comUSD 90m1.1%
5Braidwell12 funds on PPLI.comUSD 57m2.1%
6Marshall Wace LLP84 funds on PPLI.comUSD 46m0.0%
7PFM Health Sciences3 funds on PPLI.comUSD 36m3.1%
8Bridgewater Associates45 funds on PPLI.comUSD 35m0.1%
9Rock Springs Capital Management2 funds on PPLI.comUSD 24m1.2%
10Hudson Bay Capital Management8 funds on PPLI.comUSD 22m0.1%
11Sarissa Capital Management6 funds on PPLI.comUSD 20m11.0%
12Capital Fund Management S.A.12 funds on PPLI.comUSD 17m0.1%
13Grantham Mayo Van Otterloo & Co1 fund on PPLI.comUSD 12m0.0%
14Dafna Capital Management6 funds on PPLI.comUSD 9.7m1.9%
15LMR Partners2 funds on PPLI.comUSD 9.4m0.0%
16Squarepoint Ops7 funds on PPLI.comUSD 7.4m0.0%
17Verition Fund Management3 funds on PPLI.comUSD 6.9m0.0%
18IFM Investors Pty7 funds on PPLI.comUSD 4m0.0%
19CIBC Asset Management69 funds on PPLI.comUSD 3.2m0.0%
20Engineers Gate Manager1 fund on PPLI.comUSD 3.1m0.0%
21Palo Alto Investors6 funds on PPLI.comUSD 3.1m0.4%
22Citadel Advisors32 funds on PPLI.comUSD 2m0.0%
23Boothbay Fund Management2 funds on PPLI.comUSD 2m0.0%
24Millennium Management6 funds on PPLI.comUSD 2m0.0%
25Aquatic Capital Management3 funds on PPLI.comUSD 1.8m0.1%
26Landscape Capital Management4 funds on PPLI.comUSD 1.6m0.1%
27Diametric Capital2 funds on PPLI.comUSD 1.3m0.1%
28D. E. Shaw & Co.15 funds on PPLI.comUSD 944,0000.0%
29Fora Capital1 fund on PPLI.comUSD 908,0000.1%
30Magnetar Financial93 funds on PPLI.comUSD 451,0000.0%
31Walleye Capital8 funds on PPLI.comUSD 299,0000.0%
32Prelude Capital Management9 funds on PPLI.comUSD 263,0000.0%
33Persistent Asset Partners10 funds on PPLI.comUSD 74,1550.0%
34Bayforest Capital1 fund on PPLI.comUSD 23,5950.0%
35Summit Global Investments1 fund on PPLI.comUSD 4,9590.3%
Next: where it matters most
Where it matters most

For Sarissa Capital Management it is 11.0% of the book

A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.

#ManagerValue reportedShare of its book
1Sarissa Capital ManagementUSD 20m11.0%
2PFM Health SciencesUSD 36m3.1%
3BraidwellUSD 57m2.1%
4Dafna Capital ManagementUSD 9.7m1.9%
5RTW InvestmentsUSD 214m1.8%
6Rock Springs Capital ManagementUSD 24m1.2%
7Armistice CapitalUSD 90m1.1%
8Renaissance TechnologiesUSD 394m0.5%
9Palo Alto InvestorsUSD 3.1m0.4%
10Summit Global InvestmentsUSD 4,9590.3%
Next: how to read this
How to read this

What a 13F list can and cannot tell you

  • It is the manager's filing, not a fund's. Form 13F covers every account a firm runs. We cannot say which of its funds holds the shares.
  • It is a snapshot. The list shows the last day of the quarter. A manager may have bought or sold since, and trading inside the quarter leaves no trace.
  • It shows one side. Short positions, swaps and shares listed outside the United States are not reported, so a manager on this list may be hedged or net short.
  • It covers the managers we track. Our coverage is 720 managers of hedge and private funds. Banks, index funds and other institutions that file Form 13F are not counted here.
Next: questions
Questions

Questions about who holds Neurocrine Biosciences Inc

What is the ticker symbol of Neurocrine Biosciences Inc?

Neurocrine Biosciences Inc trades under the symbol NBIX on the Nasdaq. Its CUSIP, the code used on Form 13F, is 64125C109.

Which hedge funds own Neurocrine Biosciences Inc (Nasdaq: NBIX)?

35 of the 720 hedge fund managers PPLI.com tracks reported Neurocrine Biosciences Inc shares on Form 13F for 30 June 2026. The largest reported positions were held by Renaissance Technologies (USD 394m), Two Sigma Investments (USD 350m), RTW Investments (USD 214m), Armistice Capital (USD 90m) and Braidwell (USD 57m).

How many hedge funds hold Neurocrine Biosciences Inc?

35 managers in our coverage reported it, and between them they run 512 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.

Which manager has the most riding on Neurocrine Biosciences Inc?

Sarissa Capital Management, where the position was 11.0% of the reported 13F book at 30 June 2026.

Does this show who is short Neurocrine Biosciences Inc?

No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.

Important information

Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Neurocrine Biosciences Inc or with the managers listed.

Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.

Private consultation →
Step 1 of 2

Tell us about yourself

Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.

✦Research assistant
✦PPLI.comResearch assistant
Explore PPLI questions and suitability factors
Ask a general question about PPLI, or explore the factors that affect suitability. Treat the answer as a starting point and check the linked sources.
Use the research with your own tax, legal and insurance advisers.
Preparing an answer
AI assistant. Educational information only. It does not determine eligibility or provide personal tax, legal, investment or insurance advice.